DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hwz37s/lebers) has announced the addition of the "Leber's Hereditary Optic ...
Researchers from Landeskrankenhaus Salzburg (SALK) - Universitätsklinikum der PMU have identified a novel loss-of-function variant in the NDUFA7 gene in a patient with Leber’s hereditary optic ...
A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing approved treatments in the U.S.; action date of February 28, 2026 PARMA, ...
Pratteln, Switzerland, June 23, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces positive topline results from itslong-term Phase 4 LEROS study with Raxone® (idebenone) in the treatment of ...
Please provide your email address to receive an email when new articles are posted on . Idebenone has a Prescription Drug User Fee Act date of Feb. 28, 2026. Positive results in the phase 3 RHODOS and ...
NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. & the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback